Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 25

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 25
---
 by reference modifies or supersedes the statement.
Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

The information about us contained in this prospectus
supplement should be read together with the information in the documents incorporated by reference. You may request a copy of any or all
of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton,
Florida 33432, telephone number (858) 964-3720.

<div align='center'>S-12</div>

PROSPECTUS

<div align='center'>$250,000,000

INMUNE BIO Inc.

Common Stock

Preferred Stock

Warrants

Units</div>

We may from time to time, in one or more offerings
at prices and on terms that we will determine at the time of each offering, sell common stock, preferred stock, warrants, or a combination
of these securities, or units, up to a total offering price of $250,000,000.

This prospectus describes the general manner in
which our securities may be offered using this prospectus. Each time we offer and sell securities, we will provide you with a prospectus
supplement that will contain specific information about the terms of that offering. Any prospectus supplement may also add, update, or
change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as
well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities
offered hereby.

We are an “emerging growth company” under applicable Securities and Exchange Commission, rules and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.

This prospectus may not be used to offer and sell
securities unless accompanied by a prospectus supplement.

Our common stock is currently traded on The
Nasdaq Capital Market (“Nasdaq”) under the symbol “INMB.” On July 30, 2024, the last reported sales price for
our common stock was $8.26 per share. The applicable prospectus supplement will contain information, where applicable, as to any other
listing of the securities on Nasdaq or any other securities market or exchange covered by the prospectus supplement. Prospective purchasers